{
    "nctId": "NCT05670054",
    "briefTitle": "Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients",
    "officialTitle": "Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer Stage IV",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 116,
    "primaryOutcomeMeasure": "The rate of objective response and clinical benefit",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* - Pathologically proven diagnosis of adenocarcinoma of the breast with evidence of metastatic disease either progression on adjuvant hormonal or progression on 1st line hormonal for metastatic disease.\n* Documentation of ER-positive and/or PR-positive and HER2 negative.\n* Prior use of endocrine therapy.\n* age \\>18 years old.\n* ECOG: 0-2\n* Postmenopausal is defined as: age\\>60 years old or \\< 60 years old with cessation off menstruation for at least 12 months and FSH or E2 in postmenopausal range or patients who underwent bilateral oophorectomy.\n* Premenopausal is defined if not meeting the criteria of postmenopausal. They are obligated to receive LHRH agonist with their treatment.\n\nExclusion Criteria:\n\n* - Age \\< 18 years old\n* Patients with advanced/metastatic, symptomatic, visceral spread(visceral crisis) , that are at risk of life-threatening complications in the short term (including patients with massive uncontrolled effusions \\[pleural, pericardial, peritoneal\\], pulmonary lymphangitis, and over 50% liver involvement).\n* 2nd malignancy other than breast cancer\n* ECOG more than 3",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}